Board and Leadership Team

Dr James Garner is an experienced life sciences executive, whose career has focused on the development and commercialization of novel therapeutics for diseases with high unmet medical need.

Over the course of a twenty-year career in industry, James has worked principally with Biogen (NASDAQ: BIIB), Takeda (NYSE: TAK), and Sanofi (NASDAQ: SNY), in regional and global roles. He has overseen more than thirty national product approvals, more than a dozen multinational clinical trials, several partnering transactions, and numerous scientific collaborations. His experience spans multiple therapeutic areas, including oncology, immunology, CNS, and orphan diseases.

In his seven-year tenure as CEO and Managing Director of Kazia Therapeutics (NASDAQ: KZIA), James drove a transformation of the company’s pipeline by in-licensing clinical-stage assets from Genentech and Evotec, deployed an extensive pipeline of more than a dozen
clinical trials across multiple oncology indications, and inked partnering
deals with Simcere (HKSE:2096) and Vivesto AB (STO: VIVE). James has raised approximately US$ 40 million in equity financing for Kazia, and the company has also benefited significantly from non-dilutive opportunities.

In addition to his medical qualifications and MBA, James holds a master’s degree in continental philosophy and a bachelor’s degree in the history of medicine, and is a member of the Australian Institute of Company Directors (AICD) and the American Society for Clinical Oncology (ASCO).

Dr Gittleson has extensive international experience as a pharmaceutical physician and enterprise leader in pharmaceutical drug development, governance and risk management gained during her 15-year tenure (2005-2020) with global specialty biotechnology company CSL Limited (ASX: CSL).
During her time at CSL, Dr Gittleson had at various times accountability for clinical research, medical safety, medical and patient related ethics for development and on market programs, providing leadership in strategic product development, planning and implementation across multiple therapeutic and rare disease areas.

Dr Gittleson held the key leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States; and Chief Medical Officer in Melbourne from 2017 until her recent retirement from corporate roles in 2020.

Dr Price is an experienced biotech executive and entrepreneur with depth of expertise across clinical asset investment strategy, evaluation, financing and execution. Additional leadership experience within R&D, Medical, and strategic corporate functions.

Dr. Price was previously responsible for the strategic and tactical management of all business at Drug Safety Solutions. After a successful 20-year history, Drug Safety Solutions was acquired in June 2017 by Linden Capital Partners. From that date to January 2020, Dr. Price served as the Chief Medical Officer for the global ProPharma Group, a Linden subsidiary.

Over the years Dr. Price has served on multiple corporate boards, including public, private, and not-for-profit.

His board duties have included the Chairman’s role on Compensation and Governance as well as a member’s role on Audit. He has served on boards that report to; TSX, NYSE American, and NASDAQ.

His most recent experience, Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) he served on Compensation, Governance, and Business Development. In his previous role with Sarepta Therapeutics NASDAQ: SRPT, he helped to guide the company transition from $80 million market (2008) to its 2019 market cap of $8.4 billion.

Dr. Price is a clinical trial Medical Monitor and Pharmacovigilance expert. He has years of experience as the head of Safety Management Teams (SMTs), multiple Data Safety Monitoring Boards, as well as protocol development and safety support from FIH to Phase IV clinical trials.

While his therapeutic horizon is broad, it has been dominated by oncology, infectious disease, and rare disease.

Deborah Ambrosini Company Secretary and Chief Financial Officer BCom (Acc and Business Law), FCA, GIA (Cert)

Deborah Ambrosini is a highly experienced CFO and Company Secretary. She is a Fellow of Chartered Accountants Australia and New Zealand with over 20 years’ experience in leading financial strategies to facilitate growth plans. Her experience spans the biotechnology, mining, IT communications and financial services sectors.

Deborah possesses extensive experience in debt and equity capital raising activities, regulatory compliance, process improvement, investor relations, large contract management and leading all aspects of accounting, budgeting, forecasting and financial analysis. She also has significant experience both nationally and internationally in financial and business planning, compliance and taxation. Deborah has held Director roles in both listed and unlisted entities.

Deborah has been a state finalist in the Telstra Business Woman Awards. She was also named as one of the Top 40 pre-eminent business leaders in the highly prestigious WA Business News 40 under 40 awards.

Dr McKenzie is a clinical development professional with over 23 years experience in industry.
Dr McKenzie moved to global speciality biotechnology company

CSL Limited (ASX: CSL) in 1999. During his time at CSL Limited, he worked in varying roles within the Research and Development organisation including research and assay development, clinical operations, and clinical safety. For the last 11 years, Dr McKenzie was a member of the global clinical development organisation, most recently as an Associate Director. His experience spans early to late phase clinical development across multiple therapeutic areas, including vaccines, plasma derived products, immunology, respiratory, and orphan diseases.

Dr McKenzie received his PhD from the University of Melbourne in 1999.  His studies in transplantation immunology (1996-1999) were undertaken at the Walter And Eliza Hall Institute in Melbourne.